GlassScriptPhysician profile
George C Surla
NPI 1932121456
$7,185.65
in general payments reported to CMS, 2019-2025
28 companies · $1,129 in 2025
The $1,129 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $886 · 2020: $322 · 2021: $1,490 · 2022: $1,059 · 2023: $1,143 · 2024: $1,157 · 2025: $1,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,413 · Education: $15.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,413.18 |
| Education | $15.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,515.66 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $865.47 | 2019-2025 | Viberzi, Linzess |
| Gilead Sciences, INC. | $841.86 | 2019-2025 | |
| Madrigal Pharmaceuticals | $521.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $264.89 | 2021-2024 | Linzess |
| Braintree Laboratories, INC. | $261.77 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $221.85 | 2019-2024 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $187.29 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Celgene Corporation | $151.53 | 2021-2024 | Zeposia |
| Pfizer INC. | $132.28 | 2019-2023 | |
| Intercept Pharmaceuticals, INC. | $120.23 | 2021-2023 | Ocaliva |
| E.R. Squibb & Sons, L.L.C. | $117.52 | 2023 | Zeposia |
| Merck Sharp & Dohme LLC | $116.52 | 2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $106.94 | 2024-2025 | Voquezna |
| Redhill Biopharma INC. | $104.51 | 2021-2024 | Talicia |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $89.05 | 2023-2025 | Ibsrela |
| Anx Robotica Corp | $75.48 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $69.78 | 2024 | Bylvay, Iqirvo |
| Cumberland Pharmaceuticals, INC. | $60.06 | 2019-2021 | |
| Alfasigma USA, INC. | $58.83 | 2020-2021 | |
| Allergan, INC. | $51.42 | 2019 | |
| Shionogi INC | $49.21 | 2019 | |
| Ferring Pharmaceuticals INC. | $46.10 | 2019 | |
| Genzyme Corporation | $44.60 | 2022-2023 | |
| Capsovision, INC. | $38.27 | 2023-2024 | Capsocam Plus |
| Celltrion USA INC. | $27.44 | 2024 | Vegzelma |
| Novo Nordisk INC | $23.22 | 2025 | Wegovy |
| Vivus LLC | $22.23 | 2024 | Qsymia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Surla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.